New cancer drug trial launches for chinese patients with advanced tumors
NCT ID NCT05460273
Summary
This study is testing an experimental drug called Dato-DXd in Chinese patients with advanced non-small cell lung cancer or triple-negative breast cancer that has stopped responding to standard treatments. The drug is given as an IV infusion every three weeks to see if it can shrink or stop the growth of tumors. Researchers will measure how well the drug works and monitor patients for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100039, China
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100142, China
-
Research Site
Bengbu, 233004, China
-
Research Site
Changchun, 130012, China
-
Research Site
Changchun, 130021, China
-
Research Site
Chengdu, 610000, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Dalian, 116023, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Jinan, 250030, China
-
Research Site
Jinan, 250117, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanchang, 330009, China
-
Research Site
Shenyang, 110042, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.